| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.0 | 0.0 |
| Net income | -40.2 | -26.9 |
| EPS (diluted, $ a share) | $-0.84 | $-0.71 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: RAPP. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Rapport Therapeutics, Inc.: key numbers
- Share price
- $24.82Close, Nov 16
- Market cap
- $1.47B
- Shares outstanding
- 59.28MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Rapport Therapeutics, Inc.
All →Rapport Therapeutics Financial Results
Rapport Therapeutics reported third quarter 2026 financial results and highlighted positive Phase 2 topline results for RAP-219 in bipolar mania. The company is well-capitalized with $815.4 million in cash following a recent financing, providing a projected runway through the end of 2029.
- Term
- Q3 2026
“Our positive Phase 2 results in bipolar mania are transformational for Rapport, accelerating our path to becoming an industry-leading precision neuroscience company. RAP-219 now has clinical proof-of-concept in two indications across neurology and psychiatry, giving us the opportunity to serve patients in two multibillion-dollar markets.”
Abraham N. Ceesay, chief executive officer of Rapport
Rapport Therapeutics Insider James Healy Buys $20.4M of Stock
James Healy bought 969,480 shares of Rapport Therapeutics, Inc. at $21.00 a share, worth $20.4M in total on Oct 28, 2026. Shares held after the trade: 25,267 (+37.8%).
- Value
- $20.4M
- Shares
- 969,480
- Average price
- $21.00
- Holding change
- +37.8%
- Trade date
- Oct 28, 2026
Rapport Therapeutics Capital Raise of $216M
Rapport Therapeutics entered into an underwriting agreement for a public offering of 8,333,334 shares of common stock and 1,190,476 pre-funded warrants at a price of $21.00 per share. The underwriters fully exercised their option to purchase an additional 1,428,571 shares, bringing estimated net proceeds to approximately $215.7 million. The funds are intended to support clinical trials for RAP-219 and other research and development activities.
- Value
- $216M
- Counterparty
- Morgan Stanley & Co. LLC
Rapport Therapeutics CEO Abraham Ceesay Sells $64.4K of Stock
Abraham Ceesay, CEO, sold 2,210 shares of Rapport Therapeutics, Inc. at $29.16 a share, worth $64.4K in total on Oct 21, 2026. Shares held after the trade: 450,035 (-0.5%).
- Value
- $64.4K
- Shares
- 2,210
- Price
- $29.16
- Role
- CEO
- Holding change
- -0.5%
- Trade date
- Oct 21, 2026
Rapport Therapeutics Director Ramiro Sanchez Buys $98.5K of Stock
Ramiro Sanchez, Director, bought 3,600 shares of Rapport Therapeutics, Inc. at $27.35 a share, worth $98.5K in total on Oct 23, 2026. Shares held after the trade: 3,600.
- Value
- $98.5K
- Shares
- 3,600
- Price
- $27.35
- Role
- Director
- Trade date
- Oct 23, 2026
Rapport Therapeutics Director Paul M. Silva Buys $99.6K of Stock
Paul M. Silva, Director, bought 3,680 shares of Rapport Therapeutics, Inc. at $27.07 a share, worth $99.6K in total on Oct 22, 2026. Shares held after the trade: 3,680.
- Value
- $99.6K
- Shares
- 3,680
- Price
- $27.07
- Role
- Director
- Trade date
- Oct 22, 2026